Overview

A Study of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin

Status:
Not yet recruiting

Trial end date:
2024-05-14

Target enrollment:

Participant gender:

Summary

The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with Type 2 diabetes that have already been treated with basal insulin. The study consists of a 3-week screening/lead-in period, a 78-week treatment period and a 5-week safety follow-up period. The study will last up to 86 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Insulin